Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioma 6Glioblastoma 3Diffuse Intrinsic Pontine Glioma 3Meningioma 1Gliosarcoma 1Advanced Glioblastoma 1

Interventions

Temozolomide 15Radiotherapy 11Everolimus 6Bevacizumab 6Irinotecan 5Cyclophosphamide 5ribociclib 4Radiation 4Panobinostat 4TIC10 compound 3Specimen Handling 3Re-Irradiation 3Etoposide 3Dasatinib 3pembrolizumab 2nimotuzumab 2abemaciclib 2Vorinostat 2Valproic Acid 2Topotecan 2Nivolumab 2Mebendazole 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gemcitabine 2GDC-0084 2Erlotinib Hydrochloride 2Diphtheria-Tetanus Vaccine 2Cilengitide 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × TIC10 compound × CNS × Clear all
NCT05476939 2026-02-05

BIOMEDE 2

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
433 enrolled
CNS

Diffuse Intrinsic Pontine Glioma

NCT05009992 2025-12-17

PNOC022

University of California, San Francisco

Phase 2 Recruiting
360 enrolled
CNS

Diffuse Intrinsic Pontine Glioma

NCT03416530 2025-02-14

ONC201 in Pediatric H3 K27M Gliomas

Jazz Pharmaceuticals

Phase 1 Terminated
134 enrolled 1 FDA
CNS

Diffuse Intrinsic Pontine Glioma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡